Loading clinical trials...
Loading clinical trials...
A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.
Conditions
Interventions
zigakibart
Locations
6
United States
Colorado Kidney Care Nephrology
Denver, Colorado, United States
NY Nephrology
Clifton Park, New York, United States
Knoxville Kidney Center Pllc
Brentwood, Tennessee, United States
Novartis Investigative Site
Buenos Aires, Buenos Aires F.D., Argentina
Novartis Investigative Site
Santa Fe, Argentina
Novartis Investigative Site
Seoul, Korea, South Korea
Start Date
July 28, 2025
Primary Completion Date
June 25, 2031
Completion Date
June 25, 2031
Last Updated
February 6, 2026
NCT07355296
NCT06337838
NCT05318196
NCT05728216
NCT05645003
NCT06656988
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions